Skip to main content

Market Overview

Moderna Hires Amgen Executive As Chief Commercial Officer To Bolster Vaccine Marketing

Moderna Hires Amgen Executive As Chief Commercial Officer To Bolster Vaccine Marketing

Moderna Inc (NASDAQ: MRNA), which received the fourth regulatory nod for its investigational coronavirus vaccine with the conditional approval granted Wednesday by the European Union, is leaving no stone unturned in its commercialization efforts.

What Happened: Boston, Massachusetts-based Moderna said it has hired biopharma industry veteran Corinne Le Goff as chief commercial officer effective Jan. 19. She will report to CEO Stéphane Bancel, the company said.

"I am thrilled to welcome Corinne to Moderna as our chief commercial officer and to the executive committee. Corinne is joining us at an important time as we launch our COVID-19 vaccine, prepare to start the Phase 3 study of our CMV vaccine and pivot to a commercial stage company," Bancel said in a statement.

Related Link: Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates

Why It's Important: Le Geoff's appointment comes at a time Moderna has started the rollout of its vaccine candidate in the U.S., Canada, Israel and the EU.

Additional authorizations are under review in Singapore, Switzerland and the U.K. Le Goff carries a wealth of experience in roles with large-cap pharma companies such as Amgen, Inc. (NASDAQ: AMGN), Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY), Sanofi SA (NASDAQ: SNY) and Pfizer Inc. (NYSE: PFE).

Le Geoff was most recently working as senior vice president and president of the U.S. business organization of Amgen, where she was credited with the valuation and commercial integration of psoriasis medication Otelza. Amgen acquired the drug from Celgene.

She was also instrumental in driving the growth of products such as Amgen's cholesterol drug Repatha and migraine drug Aimovig.

MRNA Price Action: At last check, Moderna shares were rising 0.52% to $116.87.

Related Link: The Daily Biotech Pulse: CureVac COVID-19 Vaccine Deal, Argenx Out-Licenses Neuromuscular Disorder Drug, Xencor's Oncology Collaboration


Related Articles (MRNA)

View Comments and Join the Discussion!

Posted-In: Coronavirus Covid-19 vaccineBiotech News Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at